Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle

Diabetes

Volumn 64, Issue 9, 2015, Pages 3321-3327

  Dineen, Stacey L ^a   McKenney, Mikaela L ^a   Bell, Lauren N ^a   Fullenkamp, Allison M ^a   Schultz, Kyle A ^a   Alloosh, Mouhamad ^a   Chalasani, Naga ^a   Sturek, Michael ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 3174; CALCIUM; EXENDIN 4; FURA 2; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; AC3174; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CALORIC INTAKE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY MUSCLE; DRUG EFFECT; ENZYME ISOLATION; GLUCOSE TOLERANCE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INTRACELLULAR SIGNALING; INTRAVASCULAR ULTRASOUND; METABOLIC SYNDROME X; NONHUMAN; OSSABAW MINIATURE SWINE; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE CELL; WEIGHT GAIN; AGONISTS; ANIMAL; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; PIG; RANDOMIZATION; SECRETION (PROCESS); SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; CALCIUM; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIET, ATHEROGENIC; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INSULIN; METABOLIC SYNDROME X; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEPTIDES; RANDOM ALLOCATION; RECEPTORS, GLUCAGON; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SWINE; ULTRASONOGRAPHY; VENOMS; WEIGHT LOSS;

EID: 84962795005     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1790     Document Type: Article

References (25)

1. Go AS, Mozaffarian D, Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292
2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-414
3. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3: 153-165
4. Hargrove DM, Kendall ES, Reynolds JM, et al. Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 2007;141:113-119
5. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-590
6. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27: 256-263
7. Masoudi FA. Improving drug safety surveillance: lessons from rosiglitazone. Circ Cardiovasc Qual Outcomes 2010;3:444-446
8. Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008. Available from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed 15 October 2014
9. Timmers L, Henriques JPS, de Kleijn DPV, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and re-perfusion injury. J Am Coll Cardiol 2009;53:501-510
10. Liu Q, Anderson C, Broyde A, et al. Glucagon-like peptide-1 and the ex-enatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010;9:76
11. Hirata Y, Kurobe H, Nishio C, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol 2013;699:106-111
12. Dokken BB, Weber CS, Mitchell JL, Gold JM, Lynch RM. Glucagon-like peptide-1 modulates calcium homeostasis in human coronary microvascular endothelial cells after ischemia and reperfusion. Journal of Endocrinology, Diabetes & Obesity 2014;2:1025-1031
13. Liang CP, Han S, Li G, Tabas I, Tall AR. Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment. Diabetes 2012;61: 2609-2620
14. Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol 2013; 304:C508-C518
15. Moberly SP, Mather KJ, Berwick ZC, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol 2013;108:365
16. Neeb ZP, Edwards JM, Alloosh M, Long X, Mokelke EA, Sturek M. Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. Comp Med 2010;60:300-315
17. 2+ dysregulation in coronary smooth muscle from diabetic dyslipidemic Yucatan swine. J Appl Physiol (1985) 2006;101:752-762
18. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington, D.C., National Academy Press, 2010
19. AVMA Panel on Euthanasia. American Veterinary Medical Association. 2000 Report of the AVMA Panel on Euthanasia. J Am Vet Med Assoc 2001;218: 669-696
20. Sturek M, Alloosh M, Wenzel J, et al. Ossabaw Island miniature swine: cardiometabolic syndrome assessment. In Swine in the Laboratory: Surgery, Anesthesia, Imaging, and Experimental Techniques. 2nd ed. Swindle MM, Ed. Boca Raton, FL, CRC Press, 2007, p. 397-402
21. 2+ regulatory mechanisms of exercise protection against coronary artery disease in metabolic syndrome and diabetes. J Appl Physiol (1985) 2011;111:573-586
22. Lipskaia L, del Monte F, Capiod T, et al. Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 2005;97:488-495
23. Lipskaia L, Hadri L, Le PP, et al. SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery. Gene Ther 2013;20:396-406
24. Yoshida I, Monji A, Tashiro K, Nakamura K, Inoue R, Kanba S. Depletion of intracellular Ca2+ store itself may be a major factor in thapsigargin-induced ER stress and apoptosis in PC12 cells. Neurochem Int 2006;48:696-702
25. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215